{"protocolSection": {"identificationModule": {"nctId": "NCT04150341", "orgStudyIdInfo": {"id": "0178"}, "secondaryIdInfos": [{"id": "2019-002915-24", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Theravance Biopharma", "class": "INDUSTRY"}, "briefTitle": "Effect of Inhaled TD-8236 on Allergen-induced Asthmatic Response", "officialTitle": "A Randomized, Double-blind, Placebo-controlled, 3-period Crossover Study to Evaluate the Effects of Repeated Doses of Inhaled TD-8236 and Impact on Airway Responses Following Allergen Challenge in Patients With Asthma"}, "statusModule": {"statusVerifiedDate": "2022-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2019-11-06", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2020-08-28", "type": "ACTUAL"}, "completionDateStruct": {"date": "2020-09-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2019-10-15", "studyFirstSubmitQcDate": "2019-11-01", "studyFirstPostDateStruct": {"date": "2019-11-04", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2022-02-17", "resultsFirstSubmitQcDate": "2022-02-17", "resultsFirstPostDateStruct": {"date": "2022-03-18", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-02-17", "lastUpdatePostDateStruct": {"date": "2022-03-18", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Theravance Biopharma", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false, "isUsExport": true}, "descriptionModule": {"briefSummary": "This will be a randomized, double-blind, placebo-controlled study. The study will use a three-period, six-sequence, complete-block, cross-over study design to characterize two doses of inhaled TD-8236 compared to placebo in subjects with mild asthma and a known response to an allergen. Each of the three periods will be 14 days, followed by a washout period before the next period."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["TD-8236", "Asthma", "Proof of concept"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 24, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "TD-8236 Dose A (low dose)", "type": "EXPERIMENTAL", "description": "TD-8236 Dose A (QD x 14 days)", "interventionNames": ["Drug: TD-8236"]}, {"label": "TD-8236 Dose B (high dose)", "type": "EXPERIMENTAL", "description": "TD-8236 Dose B (QD x 14 days)", "interventionNames": ["Drug: TD-8236"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo (QD x 14 days)", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "TD-8236", "description": "The study drug will be administered by inhalation in the morning for 14 days during each period. A washout period of at least 21 days will exist between subsequent periods.", "armGroupLabels": ["TD-8236 Dose A (low dose)", "TD-8236 Dose B (high dose)"]}, {"type": "DRUG", "name": "Placebo", "description": "The placebo will be administered by inhalation in the morning for 14 days during each period. A washout period of at least 21 days will exist between subsequent periods.", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Area Under the Curve of Change From Baseline in Forced Expiratory Volume (in 1 Second) (FEV1) From 3 to 8 Hours After Inhaled Allergen Challenge at Day 14", "description": "Values are reported as a weighted mean derived by calculating the AUC change from baseline over the relative time interval, divided by the time interval.", "timeFrame": "Day 14 of treatment period: 3 to 8 hours after allergen challenge"}], "secondaryOutcomes": [{"measure": "Area Under the Curve of Percentage Change From Baseline in Forced Expiratory Volume (in 1 Second) (FEV1) From 3 to 8 Hours After Inhaled Allergen Challenge at Day 14", "description": "Values are reported as a weighted mean derived by calculating the AUC percentage change from baseline over the relative time interval, divided by the time interval.", "timeFrame": "Day 14 of treatment period: 3 to 8 hours after allergen challenge"}, {"measure": "Maximum Decline in Forced Expiratory Volume (in 1 Second) (FEV1) From 3 to 8 Hours After Inhaled Allergen Challenge at Day 14", "timeFrame": "Day 14 of treatment period: 3 to 8 hours after allergen challenge"}, {"measure": "Maximum Percentage Decline in Forced Expiratory Volume (in 1 Second) (FEV1) From 3 to 8 Hours After Inhaled Allergen Challenge at Day 14", "timeFrame": "Day 14 of treatment period: 3 to 8 hours after allergen challenge"}, {"measure": "Area Under the Concentration-time Curve Over One 24-hour Dosing Interval (AUC0-24) of TD-8236 in Plasma", "timeFrame": "Day 14 of treatment period: Pre-dose and 0.5, 1, 2, 4, 6, 8 and 24 hours post-dose"}, {"measure": "Maximum Observed Plasma Concentration (Cmax) of TD-8236 in Plasma During Dosing Interval", "timeFrame": "Day 14 of treatment period: Pre-dose and 0.5, 1, 2, 4, 6, 8 and 24 hours post-dose"}, {"measure": "Time to Maximum Observed Concentration (Tmax) of TD-8236 in Plasma Over a Dosing Interval", "timeFrame": "Day 14 of treatment period: Pre-dose and 0.5, 1, 2, 4, 6, 8 and 24 hours post-dose"}, {"measure": "Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)", "description": "A TEAE was defined as any adverse event (AE) that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus the number of days in the follow-up period.\n\nThe severity of TEAEs were also assessed and were classified as mild, moderate or severe per the definitions below:\n\nMild - The AE is noticeable to the participant and/or the investigator, but does not interfere with routine activity.\n\nModerate - The AE interferes with routine activity, but responds to symptomatic therapy or rest.\n\nSevere - The AE significantly limits the participant's ability to perform routine activities despite symptomatic therapy.", "timeFrame": "Day 1 to end of follow-up (up to approximately 98 days)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female, 18 to 65 years of age\n* Willing and able to give informed consent and comply with study requirements\n* Documented physician-diagnosed asthma for \u2265 4 months prior to Screening\n* Body mass index (BMI) \u2265 18.0 and \u2264 35.0 kg/m2 at Screening and weighs \u2265 50 kg at Screening.\n* Women of child bearing potential must have a negative pregnancy test\n* Males and females must use a highly efficient birth control method\n* Pre-bronchodilator FEV1 \u2265 70% predicted\n* Documented allergy to at least one common allergen\n* Dual responder to inhaled bronchial challenges\n* Additional inclusion criteria apply\n\nExclusion Criteria:\n\n* Positive for hepatitis A, B or C, HIV or tuberculosis\n* Clinically significant abnormalities of laboratory evaluations\n* Have abnormal ECG measurements\n* Any sign of respiratory tract infection within 6 weeks of screening\n* Have a current bacterial, parasitic, fungal or viral infection\n* History of life-threatening asthma\n* Uses or have used tobacco or nicotine-containing products within 6 months prior to screening\n* Additional exclusion criteria apply", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Theravance Biopharma", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Theravance Biopharma Investigational Site", "city": "London", "zip": "W1G 8HU", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}, {"facility": "Theravance Biopharma Investigational Site", "city": "Manchester", "zip": "M23 9QZ", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO", "description": "Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents."}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants were screened with an allergen challenge test within 35 days prior to first dosing. Participants received increasing concentrations of inhaled allergen until a decrease of \u226520% from preallergen forced expiratory volume (in 1 second) (FEV1) was observed during the 30 minutes following the most recent inhalation, and then monitored for a late asthmatic response (LAR).", "recruitmentDetails": "A total of 24 participants were enrolled at 2 sites in the United Kingdom.", "groups": [{"id": "FG000", "title": "TD-8236 150 mcg/TD-8236 1500 mcg/Placebo", "description": "Participants received TD-8236 150 mcg first, then TD-8236 1500 mcg, and then Placebo.\n\nAll treatment periods were 14 days with a 21 day washout period between treatments."}, {"id": "FG001", "title": "TD-8236 150 mcg/Placebo/TD-8236 1500 mcg", "description": "Participants received TD-8236 150 mcg first, then Placebo, and then TD-8236 1500 mcg.\n\nAll treatment periods were 14 days with a 21 day washout period between treatments."}, {"id": "FG002", "title": "Placebo/TD-8236 1500 mcg/TD-8236 150 mcg", "description": "Participants received Placebo first, then TD-8236 1500 mcg, and then TD-8236 150 mcg.\n\nAll treatment periods were 14 days with a 21 day washout period between treatments."}, {"id": "FG003", "title": "Placebo/TD-8236 150 mcg/TD-8236 1500 mcg", "description": "Participants received Placebo first, then TD-8236 150 mcg, and then TD-8236 1500 mcg.\n\nAll treatment periods were 14 days with a 21 day washout period between treatments."}, {"id": "FG004", "title": "TD-8236 1500 mcg/Placebo/TD-8236 150 mcg", "description": "Participants received TD-8236 1500 mcg first, then Placebo, and then TD-8236 150 mcg.\n\nAll treatment periods were 14 days with a 21 day washout period between treatments."}, {"id": "FG005", "title": "TD-8236 1500 mcg/TD-8236 150 mcg/Placebo", "description": "Participants received TD-8236 1500 mcg first, then TD-8236 150 mcg, and then Placebo.\n\nAll treatment periods were 14 days with a 21 day washout period between treatments."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "4"}, {"groupId": "FG004", "numSubjects": "4"}, {"groupId": "FG005", "numSubjects": "4"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "4"}, {"groupId": "FG004", "numSubjects": "3"}, {"groupId": "FG005", "numSubjects": "4"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "All Study Participants", "description": "Participants were randomized to 1 of 6 treatment sequences. Each treatment period was 14 days with a 21 day washout between treatments. All participants were randomized to receive all study drugs."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "24"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "24"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "42.0", "spread": "11.21"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "7"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "17"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "24"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "2"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "3"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "19"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Area Under the Curve of Change From Baseline in Forced Expiratory Volume (in 1 Second) (FEV1) From 3 to 8 Hours After Inhaled Allergen Challenge at Day 14", "description": "Values are reported as a weighted mean derived by calculating the AUC change from baseline over the relative time interval, divided by the time interval.", "populationDescription": "Only participants with quantifiable measurements are included here.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "liters", "timeFrame": "Day 14 of treatment period: 3 to 8 hours after allergen challenge", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants were administered inhaled doses of placebo matching TD-8236 once per day (QD) by dry powder inhaler on Day 1 to Day 14 of the 14 day treatment period. An allergen challenge was performed 1 hour after dosing on Day 14 at the dose of allergen required to achieve a successful response at screening."}, {"id": "OG001", "title": "TD-8236 150 mcg", "description": "Participants were administered 150 microgram (mcg) inhaled doses of TD-8236 once per day (QD) by dry powder inhaler on Day 1 to Day 14 of the 14 day treatment period. An allergen challenge was performed 1 hour after dosing on Day 14 at the dose of allergen required to achieve a successful response at screening."}, {"id": "OG002", "title": "TD-8236 1500 mcg", "description": "Participants were administered 1500 microgram (mcg) inhaled doses of TD-8236 once per day (QD) by dry powder inhaler on Day 1 to Day 14 of the 14 day treatment period. An allergen challenge was performed 1 hour after dosing on Day 14 at the dose of allergen required to achieve a successful response at screening."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "20"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.53", "spread": "0.077"}, {"groupId": "OG001", "value": "-0.54", "spread": "0.077"}, {"groupId": "OG002", "value": "-0.57", "spread": "0.079"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.881", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.01", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.14", "ciUpperLimit": "0.12"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.575", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.04", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.17", "ciUpperLimit": "0.1"}]}, {"type": "SECONDARY", "title": "Area Under the Curve of Percentage Change From Baseline in Forced Expiratory Volume (in 1 Second) (FEV1) From 3 to 8 Hours After Inhaled Allergen Challenge at Day 14", "description": "Values are reported as a weighted mean derived by calculating the AUC percentage change from baseline over the relative time interval, divided by the time interval.", "populationDescription": "Only participants with quantifiable measurements are included here.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage change", "timeFrame": "Day 14 of treatment period: 3 to 8 hours after allergen challenge", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants were administered inhaled doses of placebo matching TD-8236 once per day (QD) by dry powder inhaler on Day 1 to Day 14 of the 14 day treatment period. An allergen challenge was performed 1 hour after dosing on Day 14 at the dose of allergen required to achieve a successful response at screening."}, {"id": "OG001", "title": "TD-8236 150 mcg", "description": "Participants were administered 150 microgram (mcg) inhaled doses of TD-8236 once per day (QD) by dry powder inhaler on Day 1 to Day 14 of the 14 day treatment period. An allergen challenge was performed 1 hour after dosing on Day 14 at the dose of allergen required to achieve a successful response at screening."}, {"id": "OG002", "title": "TD-8236 1500 mcg", "description": "Participants were administered 1500 microgram (mcg) inhaled doses of TD-8236 once per day (QD) by dry powder inhaler on Day 1 to Day 14 of the 14 day treatment period. An allergen challenge was performed 1 hour after dosing on Day 14 at the dose of allergen required to achieve a successful response at screening."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-16.92", "spread": "2.512"}, {"groupId": "OG001", "value": "-17.50", "spread": "2.516"}, {"groupId": "OG002", "value": "-17.97", "spread": "2.562"}]}]}]}, {"type": "SECONDARY", "title": "Maximum Decline in Forced Expiratory Volume (in 1 Second) (FEV1) From 3 to 8 Hours After Inhaled Allergen Challenge at Day 14", "populationDescription": "Only participants with available data are included.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "liters", "timeFrame": "Day 14 of treatment period: 3 to 8 hours after allergen challenge", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants were administered inhaled doses of placebo matching TD-8236 once per day (QD) by dry powder inhaler on Day 1 to Day 14 of the 14 day treatment period. An allergen challenge was performed 1 hour after dosing on Day 14 at the dose of allergen required to achieve a successful response at screening."}, {"id": "OG001", "title": "TD-8236 150 mcg", "description": "Participants were administered 150 microgram (mcg) inhaled doses of TD-8236 once per day (QD) by dry powder inhaler on Day 1 to Day 14 of the 14 day treatment period. An allergen challenge was performed 1 hour after dosing on Day 14 at the dose of allergen required to achieve a successful response at screening."}, {"id": "OG002", "title": "TD-8236 1500 mcg", "description": "Participants were administered 1500 microgram (mcg) inhaled doses of TD-8236 once per day (QD) by dry powder inhaler on Day 1 to Day 14 of the 14 day treatment period. An allergen challenge was performed 1 hour after dosing on Day 14 at the dose of allergen required to achieve a successful response at screening."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "20"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.83", "spread": "0.082"}, {"groupId": "OG001", "value": "-0.86", "spread": "0.082"}, {"groupId": "OG002", "value": "-0.85", "spread": "0.084"}]}]}]}, {"type": "SECONDARY", "title": "Maximum Percentage Decline in Forced Expiratory Volume (in 1 Second) (FEV1) From 3 to 8 Hours After Inhaled Allergen Challenge at Day 14", "populationDescription": "Only participants with available data are included.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage change", "timeFrame": "Day 14 of treatment period: 3 to 8 hours after allergen challenge", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants were administered inhaled doses of placebo matching TD-8236 once per day (QD) by dry powder inhaler on Day 1 to Day 14 of the 14 day treatment period. An allergen challenge was performed 1 hour after dosing on Day 14 at the dose of allergen required to achieve a successful response at screening."}, {"id": "OG001", "title": "TD-8236 150 mcg", "description": "Participants were administered 150 microgram (mcg) inhaled doses of TD-8236 once per day (QD) by dry powder inhaler on Day 1 to Day 14 of the 14 day treatment period. An allergen challenge was performed 1 hour after dosing on Day 14 at the dose of allergen required to achieve a successful response at screening."}, {"id": "OG002", "title": "TD-8236 1500 mcg", "description": "Participants were administered 1500 microgram (mcg) inhaled doses of TD-8236 once per day (QD) by dry powder inhaler on Day 1 to Day 14 of the 14 day treatment period. An allergen challenge was performed 1 hour after dosing on Day 14 at the dose of allergen required to achieve a successful response at screening."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "20"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-27.02", "spread": "2.790"}, {"groupId": "OG001", "value": "-28.18", "spread": "2.794"}, {"groupId": "OG002", "value": "-26.88", "spread": "2.843"}]}]}]}, {"type": "SECONDARY", "title": "Area Under the Concentration-time Curve Over One 24-hour Dosing Interval (AUC0-24) of TD-8236 in Plasma", "populationDescription": "Only participants with quantifiable measurements are included here.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "h*ng/mL", "timeFrame": "Day 14 of treatment period: Pre-dose and 0.5, 1, 2, 4, 6, 8 and 24 hours post-dose", "groups": [{"id": "OG000", "title": "TD-8236 150 mcg", "description": "Participants were administered 150 microgram (mcg) inhaled doses of TD-8236 once per day (QD) by dry powder inhaler on Day 1 to Day 14 of the 14 day treatment period. An allergen challenge was performed 1 hour after dosing on Day 14 at the dose of allergen required to achieve a successful response at screening."}, {"id": "OG001", "title": "TD-8236 1500 mcg", "description": "Participants were administered 1500 microgram (mcg) inhaled doses of TD-8236 once per day (QD) by dry powder inhaler on Day 1 to Day 14 of the 14 day treatment period. An allergen challenge was performed 1 hour after dosing on Day 14 at the dose of allergen required to achieve a successful response at screening."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "20"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.482", "spread": "48.8"}, {"groupId": "OG001", "value": "1.54", "spread": "70.6"}]}]}]}, {"type": "SECONDARY", "title": "Maximum Observed Plasma Concentration (Cmax) of TD-8236 in Plasma During Dosing Interval", "populationDescription": "Only participants with quantifiable measurements are included here.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ng/mL", "timeFrame": "Day 14 of treatment period: Pre-dose and 0.5, 1, 2, 4, 6, 8 and 24 hours post-dose", "groups": [{"id": "OG000", "title": "TD-8236 150 mcg", "description": "Participants were administered 150 microgram (mcg) inhaled doses of TD-8236 once per day (QD) by dry powder inhaler on Day 1 to Day 14 of the 14 day treatment period. An allergen challenge was performed 1 hour after dosing on Day 14 at the dose of allergen required to achieve a successful response at screening."}, {"id": "OG001", "title": "TD-8236 1500 mcg", "description": "Participants were administered 1500 microgram (mcg) inhaled doses of TD-8236 once per day (QD) by dry powder inhaler on Day 1 to Day 14 of the 14 day treatment period. An allergen challenge was performed 1 hour after dosing on Day 14 at the dose of allergen required to achieve a successful response at screening."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "21"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.0207", "spread": "46.4"}, {"groupId": "OG001", "value": "0.160", "spread": "54.3"}]}]}]}, {"type": "SECONDARY", "title": "Time to Maximum Observed Concentration (Tmax) of TD-8236 in Plasma Over a Dosing Interval", "populationDescription": "Only participants with quantifiable measurements are included here.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "hours", "timeFrame": "Day 14 of treatment period: Pre-dose and 0.5, 1, 2, 4, 6, 8 and 24 hours post-dose", "groups": [{"id": "OG000", "title": "TD-8236 150 mcg", "description": "Participants were administered 150 microgram (mcg) inhaled doses of TD-8236 once per day (QD) by dry powder inhaler on Day 1 to Day 14 of the 14 day treatment period. An allergen challenge was performed 1 hour after dosing on Day 14 at the dose of allergen required to achieve a successful response at screening."}, {"id": "OG001", "title": "TD-8236 1500 mcg", "description": "Participants were administered 1500 microgram (mcg) inhaled doses of TD-8236 once per day (QD) by dry powder inhaler on Day 1 to Day 14 of the 14 day treatment period. An allergen challenge was performed 1 hour after dosing on Day 14 at the dose of allergen required to achieve a successful response at screening."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "21"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.950", "lowerLimit": "0.483", "upperLimit": "1.03"}, {"groupId": "OG001", "value": "0.550", "lowerLimit": "0.467", "upperLimit": "1.07"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)", "description": "A TEAE was defined as any adverse event (AE) that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus the number of days in the follow-up period.\n\nThe severity of TEAEs were also assessed and were classified as mild, moderate or severe per the definitions below:\n\nMild - The AE is noticeable to the participant and/or the investigator, but does not interfere with routine activity.\n\nModerate - The AE interferes with routine activity, but responds to symptomatic therapy or rest.\n\nSevere - The AE significantly limits the participant's ability to perform routine activities despite symptomatic therapy.", "populationDescription": "Only participants with available data are included.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Day 1 to end of follow-up (up to approximately 98 days)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants were administered inhaled doses of placebo matching TD-8236 once per day (QD) by dry powder inhaler on Day 1 to Day 14 of the 14 day treatment period. An allergen challenge was performed 1 hour after dosing on Day 14 at the dose of allergen required to achieve a successful response at screening."}, {"id": "OG001", "title": "TD-8236 150 mcg", "description": "Participants were administered 150 microgram (mcg) inhaled doses of TD-8236 once per day (QD) by dry powder inhaler on Day 1 to Day 14 of the 14 day treatment period. An allergen challenge was performed 1 hour after dosing on Day 14 at the dose of allergen required to achieve a successful response at screening."}, {"id": "OG002", "title": "TD-8236 1500 mcg", "description": "Participants were administered 1500 microgram (mcg) inhaled doses of TD-8236 once per day (QD) by dry powder inhaler on Day 1 to Day 14 of the 14 day treatment period. An allergen challenge was performed 1 hour after dosing on Day 14 at the dose of allergen required to achieve a successful response at screening."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "23"}, {"groupId": "OG002", "value": "24"}]}], "classes": [{"title": "Any TEAE", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "9"}, {"groupId": "OG002", "value": "9"}]}]}, {"title": "Moderate or Severe TEAE", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "2"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Day 1 to end of follow-up (up to approximately 98 days)", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Participants were administered inhaled doses of placebo matching TD-8236 once per day (QD) by dry powder inhaler on Day 1 to Day 14 of the 14 day treatment period. An allergen challenge was performed 1 hour after dosing on Day 14 at the dose of allergen required to achieve a successful response at screening.", "deathsNumAffected": 0, "deathsNumAtRisk": 24, "seriousNumAffected": 0, "seriousNumAtRisk": 24, "otherNumAffected": 10, "otherNumAtRisk": 24}, {"id": "EG001", "title": "TD-8236 150 mcg", "description": "Participants were administered 150 microgram (mcg) inhaled doses of TD-8236 once per day (QD) by dry powder inhaler on Day 1 to Day 14 of the 14 day treatment period. An allergen challenge was performed 1 hour after dosing on Day 14 at the dose of allergen required to achieve a successful response at screening.", "deathsNumAffected": 0, "deathsNumAtRisk": 23, "seriousNumAffected": 0, "seriousNumAtRisk": 23, "otherNumAffected": 9, "otherNumAtRisk": 23}, {"id": "EG002", "title": "TD-8236 1500 mcg", "description": "Participants were administered 1500 microgram (mcg) inhaled doses of TD-8236 once per day (QD) by dry powder inhaler on Day 1 to Day 14 of the 14 day treatment period. An allergen challenge was performed 1 hour after dosing on Day 14 at the dose of allergen required to achieve a successful response at screening.", "deathsNumAffected": 0, "deathsNumAtRisk": 24, "seriousNumAffected": 0, "seriousNumAtRisk": 24, "otherNumAffected": 9, "otherNumAtRisk": 24}], "otherEvents": [{"term": "Exposure to SARS-CoV-2", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (23.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 24}]}, {"term": "Injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (23.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Joint dislocation", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (23.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Joint injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (23.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Blood creatine phosphokinase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (23.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Liver function test abnormal", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (23.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Forced expiratory volume decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (23.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "SARS-CoV-2 test positive", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (23.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 24}]}, {"term": "Seasonal allergy", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA (23.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (23.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Nasal congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (23.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (23.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 24}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (23.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 24}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (23.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numEvents": 7, "numAffected": 5, "numAtRisk": 23}, {"groupId": "EG002", "numEvents": 5, "numAffected": 4, "numAtRisk": 24}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (23.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Episcleritis", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA (23.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Chest discomfort", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (23.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (23.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (23.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 24}]}, {"term": "Toothache", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (23.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (23.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (23.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 24}]}, {"term": "Dermatitis allergic", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (23.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Musculoskeletal chest pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (23.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (23.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 24}]}, {"term": "Conjunctivitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (23.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Lower respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (23.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Suspected COVID-19", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (23.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 24}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (23.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 23}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 24}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Nathan Pfeifer", "organization": "Theravance Biopharma US, Inc", "email": "npfeifer@theravance.com", "phone": "001 (650) 808-3711"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2019-11-05", "uploadDate": "2022-02-16T17:36", "filename": "Prot_000.pdf", "size": 1259808}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2020-09-21", "uploadDate": "2022-02-16T17:38", "filename": "SAP_001.pdf", "size": 1168725}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}}, "hasResults": true}